Technical Analysis for MACK - Merrimack Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 5.0 0.40% 0.02
MACK closed up 0.4 percent on Friday, January 18, 2019, on 47 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical MACK trend table...

Date Alert Name Type % Chg
Jan 18 Stochastic Reached Overbought Strength 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 17 Calm After Storm Range Contraction 0.40%
Jan 17 Wide Bands Range Expansion 0.40%
Jan 17 Overbought Stochastic Strength 0.40%
Jan 16 Wide Bands Range Expansion 1.21%
Jan 16 Overbought Stochastic Strength 1.21%
Jan 15 Slingshot Bullish Bullish Swing Setup 3.73%

Older signals for MACK ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer in the United States. The company uses its Network Biology proprietary systems biology-based approach to biomedical research. Its therapeutic oncology candidates in clinical development include MM-398, a stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan, which is in multiple ongoing Phase I, Phase II, Phase III clinical trials for various cancers; MM-121, a fully human monoclonal antibody that targets ErbB3, a cell surface receptor implicated in cancer, which is in multiple ongoing Phase I and Phase II clinical trials; and MM-111, a bispecific antibody designed to inhibit ErbB3 signaling in cancer cells that are characterized by overexpression of the ErbB2 cell receptor, which is in multiple ongoing Phase I and Phase II clinical trials. The company's product candidates also include MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor in Phase 1 clinical trial in patients with advanced ErbB2 positive breast cancer; MM-151, an oligoclonal therapeutic consisting of a mixture of three human antibody antagonists, which is in Phase I clinical trial; and MM-141, a human tetravalent bispecific antibody designed to inhibit signaling of the PI3K/AKT/mTOR pathway initiated by the insulin-like growth factor 1 receptor(IGF-1R) and ErbB3, which is in Phase 1 clinical trial. It has collaboration and license agreements with Sanofi; Dyax Corp.; PharmaEngine, Inc.; Adimab LLC; University of California; U.S. Public Health Service; and Selexis SA. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Is MACK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.7
52 Week Low 3.34
Average Volume 80,025
200-Day Moving Average 5.9646
50-Day Moving Average 4.4072
20-Day Moving Average 4.473
10-Day Moving Average 4.921
Average True Range 0.2405
ADX 27.16
+DI 24.3723
-DI 16.2878
Chandelier Exit (Long, 3 ATRs ) 4.5485
Chandelier Exit (Short, 3 ATRs ) 4.4215
Upper Bollinger Band 5.4239
Lower Bollinger Band 3.5221
Percent B (%b) 0.78
BandWidth 42.517326
MACD Line 0.2147
MACD Signal Line 0.1497
MACD Histogram 0.0651
Fundamentals Value
Market Cap 66.4 Million
Num Shares 13.3 Million
EPS 32.12
Price-to-Earnings (P/E) Ratio 0.16
Price-to-Sales 1.06
Price-to-Book 1.44
PEG Ratio 0.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.35
Resistance 3 (R3) 5.32 5.18 5.29
Resistance 2 (R2) 5.18 5.09 5.19 5.27
Resistance 1 (R1) 5.09 5.04 5.14 5.12 5.25
Pivot Point 4.95 4.95 4.97 4.96 4.95
Support 1 (S1) 4.86 4.86 4.91 4.89 4.75
Support 2 (S2) 4.72 4.81 4.73 4.73
Support 3 (S3) 4.63 4.72 4.71
Support 4 (S4) 4.66